Gynecologic Oncologic Imaging With PET/CT
FDG-PET/CT has been evaluated in a variety of gynecologic malignancies in a variety of settings and is approved by the Centers for Medicare & Medicaid Services for the initial and subsequent treatment strategies of these malignancies. Cervical cancer is typically very FDG avid, and FDG-PET/CT appears to be most valuable for initial staging, radiation therapy planning, and detection of recurrent disease. For ovarian cancer, the most value of FDG-PET/CT appears to be for detecting recurrent disease in the setting of rising CA-125 level and negative or equivocal anatomical imaging studies.
Source: Seminars in Nuclear Medicine - Category: Radiology Authors: Paul Grant, Christopher Sakellis, Heather A. Jacene Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Grants | Medicaid | Medicare | Ovarian Cancer | Ovaries | Radiation Therapy | Radiology | Study